Active Ingredient History
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Nasopharyngeal Neoplasms (approved 2023)
Angiogenesis Modulating Agents (Phase 2)
Antineoplastic Agents (Phase 2)
Anus Neoplasms (Phase 2)
Bevacizumab (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 3)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 3)
Chemoradiotherapy (Phase 1/Phase 2)
Cholangiocarcinoma (Phase 3)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Death (Phase 1)
Dendritic Cells (Phase 2)
Digestive System Neoplasms (Phase 2)
DNA Mismatch Repair (Phase 2)
Drugs, Investigational (Phase 3)
Drug Therapy (Phase 3)
Endometrial Neoplasms (Phase 1/Phase 2)
Epstein-Barr Virus Infections (Early Phase 1)
Esophageal Neoplasms (Phase 3)
Esophageal Squamous Cell Carcinoma (Phase 4)
Female Urogenital Diseases (Phase 2)
Gastrointestinal Microbiome (Phase 1/Phase 2)
General Surgery (Phase 3)
Genes, erbB-2 (Phase 3)
Gestational Trophoblastic Disease (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 1)
Herpesvirus 4, Human (Phase 2)
Hodgkin Disease (Phase 3)
Hypopharyngeal Neoplasms (Phase 2)
Immune Checkpoint Inhibitors (Phase 2)
Immunoconjugates (Phase 2)
Immunotherapy (Phase 2/Phase 3)
Induction Chemotherapy (Phase 1/Phase 2)
Kidney Diseases (Phase 2)
Kidney Neoplasms (Phase 2)
Killer Cells, Natural (Phase 2)
Laryngeal Neoplasms (Phase 2)
Liposarcoma (Phase 1/Phase 2)
Liver Neoplasms (Phase 3)
Lung Diseases (Phase 2)
Lung Neoplasms (Phase 1/Phase 2)
Lymphoma (Phase 1/Phase 2)
Lymphoma, B-Cell (Phase 1/Phase 2)
Lymphoma, Extranodal NK-T-Cell (Phase 2)
Lymphoma, Follicular (Phase 1/Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Anaplastic (Phase 1/Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 1/Phase 2)
Lymphoma, T-Cell (Phase 3)
Male Urogenital Diseases (Phase 2)
Melanoma (Phase 3)
Mesothelioma, Malignant (Phase 2)
Microsatellite Instability (Phase 1)
Mouth Neoplasms (Phase 1)
Mutation (Phase 2)
Nasopharyngeal Carcinoma (Phase 3)
Nasopharyngeal Diseases (Phase 2)
Nasopharyngeal Neoplasms (Phase 2)
Neoadjuvant Therapy (Phase 2/Phase 3)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 3)
Neuroendocrine Tumors (Phase 3)
Oocytes (Phase 2)
Ovarian Neoplasms (Phase 2)
Oxaliplatin (Phase 2)
Pancreatic Neoplasms (Phase 2)
Penile Neoplasms (Phase 2)
Perioperative Period (Phase 2)
Proto-Oncogene Proteins c-met (Phase 2)
Radiation (Phase 3)
Radiotherapy (Phase 3)
Rectal Neoplasms (Phase 2)
Rituximab (Phase 2)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 2)
Small Cell Lung Carcinoma (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 2/Phase 3)
Stomach Neoplasms (Phase 3)
Survival (Phase 2/Phase 3)
Thoracic Neoplasms (Phase 2)
Thymoma (Phase 2)
Thyroid Neoplasms (Phase 2)
Tracheal Neoplasms (Phase 2)
Transplants (Early Phase 1)
Triple Negative Breast Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2/Phase 3)
Urogenital Diseases (Phase 2)
Urogenital Neoplasms (Phase 2)
Urologic Diseases (Phase 2)
Urologic Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue